MetLife Investment Management’s Exelixis EXEL Stock Holding History

MetLife Investment Management’s Portfolio EXEL Stock Details EXEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.89M	Sell	137,441 -3,769	-3%	-$162K	0.03%	554
2025 Q4	$6.19M	Sell	141,210 -7,152	-5%	-$296K	0.03%	531
2025 Q3	$6.13M	Sell	148,362 -8,369	-5%	-$336K	0.03%	547
2025 Q2	$6.91M	Sell	156,731 -8,886	-5%	-$355K	0.04%	439
2025 Q1	$6.11M	Sell	165,617 -5,592	-3%	-$199K	0.03%	524
2024 Q4	$5.7M	Buy	171,209 +12,894	+8%	+$418K	0.03%	483
2024 Q3	$4.11M	Sell	158,315 -6,051	-4%	-$150K	0.02%	633
2024 Q2	$3.69M	Sell	164,366 -11,640	-7%	-$258K	0.02%	653
2024 Q1	$4.18M	Sell	176,006 -8,960	-5%	-$199K	0.03%	596
2023 Q4	$4.44M	Sell	184,966 -7,394	-4%	-$161K	0.03%	534
2023 Q3	$4.2M	Sell	192,360 -12,545	-6%	-$262K	0.03%	503
2023 Q2	$3.92M	Sell	204,905 -4,785	-2%	-$92.2K	0.03%	596
2023 Q1	$4.07M	Sell	209,690 -4,149	-2%	-$72.3K	0.03%	581
2022 Q4	$3.43M	Sell	213,839 -4,074	-2%	-$66.4K	0.03%	657
2022 Q3	$3.42M	Sell	217,913 -1,769	-0.8%	-$34.2K	0.03%	614
2022 Q2	$4.57M	Buy	219,682 +3,349	+2%	+$69K	0.04%	473
2022 Q1	$4.9M	Buy	216,333 +63,003	+41%	+$1.23M	0.03%	543
2021 Q4	$2.8M	Buy	153,330 +1,978	+1%	+$37.8K	0.02%	707
2021 Q3	$3.2M	Sell	151,352 -5,240	-3%	-$97.3K	0.03%	605
2021 Q2	$2.85M	Sell	156,592 -4,563	-3%	-$106K	0.03%	705
2021 Q1	$3.64M	Sell	161,155 -8,615	-5%	-$195K	0.03%	567
2020 Q4	$3.41M	Sell	169,770 -7,142	-4%	-$150K	0.03%	560
2020 Q3	$4.33M	Sell	176,912 -5,198	-3%	-$121K	0.05%	364
2020 Q2	$4.32M	Buy	182,110 +7,699	+4%	+$178K	0.05%	353
2020 Q1	$3M	Hold	174,411	–	–	0.04%	438
2019 Q4	$3.07M	Sell	174,411 -1,767	-1%	-$30K	0.03%	617
2019 Q3	$3.12M	Sell	176,178 -2,607	-1%	-$52.8K	0.03%	578
2019 Q2	$3.82M	Sell	178,785 -4,159	-2%	-$87.2K	0.04%	483
2019 Q1	$4.35M	Buy	182,944 +642	+0.4%	+$14.6K	0.05%	399
2018 Q4	$3.59M	Sell	182,302 -177,410	-49%	-$3.16M	0.04%	429
2018 Q3	$6.37M	Buy	+359,712	New	+$7.01M	0.07%	272

Other funds holding EXEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

MetLife Investment Management's EXEL Position: Q1 2026 in Review

MetLife Investment Management reduced its Exelixis (EXEL) stake by 2.7% in Q1 2026, selling an estimated $162K and leaving 137,441 shares worth $5.89M. The position accounts for 0.03% of the portfolio, ranked #554.

MetLife Investment Management first reported a position in EXEL in Q3 2018 and has held it in 31 quarters since. The position peaked at $6.91M in Q2 2025. 694 funds tracked by Wall St. Rank hold EXEL as of Q1 2026.

MetLife Investment Management held 137,441 shares of Exelixis worth $5.89M as of Q1 2026.
MetLife Investment Management sold 3,769 Exelixis shares in Q1 2026, an estimated $162K.
Exelixis made up 0.03% of MetLife Investment Management's portfolio in Q1 2026, its #554 holding.
MetLife Investment Management first reported a position in Exelixis in Q3 2018 and has held it in 31 quarters since.
MetLife Investment Management's Exelixis position peaked at $6.91M in Q2 2025.
694 funds tracked by Wall St. Rank held Exelixis as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.